カラ・ビオ
KALA BIO, Inc.
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.20 | $0 | -$3M |
| 2025 Q4 | 0.08 | $0 | -$5M |
| 2025 Q3 | -1.07 | $0 | -$11M |
| 2025 Q2 | -1.71 | $0 | -$8M |
| 2025 Q1 | -1.41 | $0 | -$9M |
| 2024 Q4 | -1.74 | $0 | -$5M |
| 2024 Q3 |
| -1.93 |
| $0 |
| -$5M |
| 2024 Q2 | -3.16 | $0 | -$9M |